Repligen Corporation, a life sciences company focused on bioprocessing technology, has recently declared the commercial launch of its single-use version of XCell⢠ATF, a proprietary cell retention system used by biologic drug manufacturers to intensify cell culture and improve the efficiency and productivity of upstream processes. This innovative new single-use format, which will be offered alongside the existing stainless steel line, significantly reduces implementation time and improves overall ease of use for Repligenâs biopharmaceutical manufacturing customers. The new XCell ATF format aligns with single-use and continuous processing workflows that biomanufacturers are increasingly adopting for their flexibility, convenience and cost-saving advantages.
Repligen will initially offer the single-use version of XCell ATF in sizes suitable for lab-scale and production-scale biopharmaceutical manufacturing. Christine Gebski, Vice President Product Management and Field Applications said, âWe expect the availability of XCell ATF technology in a convenient, gamma-sterilized, single-use format to drive increased evaluation and penetration of this perfusion tool in the marketplace. In beta site evaluations, the single-use format reduced implementation time by over 80% while delivering consistent high performance, equivalent to the stainless steel format.â?